Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05293171 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
A Phase 1 study, sponsored by BioLineRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05293171: Completed Phase 1 study, sponsored by BioLineRx.
NCT05293171 is a Phase 1 study that has completed, run by BioLineRx. The registered enrollment target is 38 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05293171, a Phase 1 study, has completed, sponsored by BioLineRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study will assess the corrected QT (QTc) effects (electrocardiogram \[ECG\]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.
Interventions
- DRUG 1.25 mg/kg BL-8040 + BL-8040-matching placebo
- DRUG 2 mg/kg BL-8040
- DRUG BL-8040-matching placebo
- DRUG 400 mg Moxifloxacin (1x400 mg tablet)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-06-11 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05293171
The ClinicalTrials.gov registry entry for NCT05293171 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioLineRx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 1.25 mg/kg BL-8040 + BL-8040-matching placebo is the first listed.
NCT05293171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05293171 about?
NCT05293171 is a clinical study titled "Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects". The study will assess the corrected QT (QTc) effects (electrocardiogram \[ECG\]) of motixafortide (BL-8040) 1.25 mg/kg (therapeutic dose) and 2 mg/kg (supratherapeutic dose) following a single subcutaneous (SC) injection relative to placebo in approximately 40 healthy subjects.
What is the current status of trial NCT05293171?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2021-06-11. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT05293171?
The interventions under investigation include: 1.25 mg/kg BL-8040 + BL-8040-matching placebo (DRUG), 2 mg/kg BL-8040 (DRUG), BL-8040-matching placebo (DRUG), 400 mg Moxifloxacin (1x400 mg tablet) (DRUG).
Who is sponsoring clinical trial NCT05293171?
This trial is sponsored by BioLineRx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.